如今，在一项新的研究中，来自肯塔基大学马基癌症中心的研究人员发现了一种蛋白，它可能是开发三阴性乳腺癌新疗法的关键。相关研究结果近期发表在 Molecular Cancer 期刊上，论文标题为 “NAC1 promotes stemness and regulates myeloid-derived cell status in triple-negative breast cancer”。

The Wistar Institute's Nan Zhang, Ph.D., assistant professor in the Ellen and Ronald Caplan Cancer Center's Molecular and Cellular Oncogenesis Program, and colleagues have discovered a new approach to ...

Gastrointestinal (GI) cancers are among the most common cancer types affecting millions worldwide with a poor survival rate ...

Vaidehi Mahajan said To improve cancer care, we need to focus on giving healthcare providers immediate access to the ...

A defining feature of many cancers is genomic instability, which refers to the increased likelihood of acquiring mutations during cell division. These alterations can serve as potential biomarkers for ...

A new nuclear medicine and molecular radiotherapy suite is streamlining and personalising cancer care, as Professor Jon ...

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) ...

AstraZeneca, in partnership with the Moi Teaching & Referral Hospital (MTRH), has launched an advanced molecular testing ...

(NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer ... AACR Symposium on Molecular Targets and ...